Access Statistics for Paolo Pertile

Author contact details at EconPapers.

Working Paper File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response 1 1 1 183 1 7 22 396
DRGs: the link between investment in technologies and appropriateness 0 0 0 27 0 4 15 137
Dynamic, economic approaches to HTA under uncertainty 0 0 0 45 0 2 3 175
Dynamic, incentive-compatible contracting for health services 1 1 1 8 1 5 16 29
Dynamic, incentive-compatible contracting for health services 0 0 0 11 0 2 14 24
Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence 1 1 3 155 3 10 36 423
Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation 1 1 1 59 2 2 10 164
L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC 0 0 0 20 2 3 13 124
Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution 0 0 0 18 1 5 19 173
Optimal sequential sampling rules for the economic evaluation of health technologies 0 0 0 86 1 2 10 261
Pricing policies when patients are heterogeneous: a welfare analysis 0 0 0 17 0 0 5 59
Public finance consolidation and fairness across living generations: the case of Italy 0 0 0 70 1 8 17 203
Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden 0 1 1 65 0 3 8 113
R&D and market size: who benefits from orphan drug regulation? 0 0 0 76 0 4 12 209
Redistribution at the Local Level: The Case of Public Childcare in Italy 0 0 0 37 0 3 17 148
Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany 2 2 5 28 4 4 27 92
Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules 0 0 0 40 1 1 5 134
The dynamics of pharmaceutical regulation and R&D investments 0 0 0 77 0 2 12 231
Who should monitor job sick leave? 0 0 0 28 0 2 7 122
Total Working Papers 6 7 12 1,050 17 69 268 3,217

Journal Article File Downloads Abstract Views
Last month 3 months 12 months Total Last month 3 months 12 months Total
A Bayesian decision theoretic model of sequential experimentation with delayed response 0 0 0 3 0 2 8 39
A large scale OLG model for the analysis of the redistributive effects of policy reforms 0 0 0 43 2 9 33 163
A reply to “Who would benefit from average value‐based pricing?” 0 0 2 5 0 2 6 25
An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography 0 0 0 16 1 3 4 90
Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” 0 0 0 3 0 4 7 34
Investment in Health Technologies in a Competitive Model with Real Options 0 0 0 34 0 4 10 120
Job sick leave: Detecting opportunistic behavior 0 0 0 8 0 3 16 49
Late-stage pharmaceutical R&D and pricing policies under two-stage regulation 0 0 0 9 2 3 10 70
Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies 0 0 0 18 0 2 9 72
Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective 0 0 0 17 0 1 11 74
R&D and market size: Who benefits from orphan drug legislation? 0 1 1 5 0 9 19 49
Redistribution at the local level: the case of public childcare in Italy 0 0 0 4 0 3 9 62
Static and dynamic efficiency of irreversible health care investments under alternative payment rules 1 1 1 22 1 7 13 160
Technology adoption, quality and health care costs: a review of the literature 0 0 0 4 0 8 13 44
The Dynamics of Pharmaceutical Regulation and R&D Investments 0 0 0 10 0 2 10 74
The fiscal disadvantage of young Italians: a new view on consolidation and fairness 0 0 0 33 0 5 20 220
The impact of managed entry agreements on pharmaceutical prices 0 0 1 16 0 5 20 98
The timing of adoption of positron emission tomography: a real options approach 0 0 0 18 1 2 8 95
Two-part payments for the reimbursement of investments in health technologies 0 0 0 13 2 5 15 68
Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition 0 0 1 10 0 0 4 56
Which valued‐based price when patients are heterogeneous? 0 0 0 12 0 2 6 44
Total Journal Articles 1 2 6 303 9 81 251 1,706

logo

LogEc Home

Top Working Papers
Top Journal Articles
Top Books
Top Chapters
Top Software Items

Top Authors

Top Working Paper series and Journals

About LogEc

Authors with papers registered in the RePEc Author Service.

Register yourself as an author or register more papers in the RePEc Author Service.

Authors with no registered papers

RePEc
LogEc provides access and usage statistics for services based on the RePEc data set.

Örebro UniversityLogEc is hosted by the Örebro University School of Business.

Questions or comments? Please see our explanation of how the statistics are collected or e-mail

Since October 2025, abstract view statistics are potentially heavily influenced by traffic from AI bots and tools that we could not eliminate despite our best efforts.

Statistics updated 2026-06-04